Metastatic non-clear cell renal cell carcinoma: An evidence based review of current treatment strategies

Alexander I. Sankin, A. Ari Hakimi, James J. Hsieh, Ana M. Molina

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

Original languageEnglish (US)
Article number67
JournalFrontiers in Oncology
Volume5
Issue numberAPR
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Therapeutics
Drug Approval
Sirolimus
United States Food and Drug Administration
Standard of Care
Vascular Endothelial Growth Factor A
Clear-cell metastatic renal cell carcinoma
Clinical Trials
Kidney
Neoplasms

Keywords

  • Metastatic
  • Non-clear cell
  • Renal cell carcinoma
  • Targeted agents
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Metastatic non-clear cell renal cell carcinoma : An evidence based review of current treatment strategies. / Sankin, Alexander I.; Hakimi, A. Ari; Hsieh, James J.; Molina, Ana M.

In: Frontiers in Oncology, Vol. 5, No. APR, 67, 2015.

Research output: Contribution to journalArticle

@article{e6b2cfe9b4ba4c3cb7928d75a19a4e69,
title = "Metastatic non-clear cell renal cell carcinoma: An evidence based review of current treatment strategies",
abstract = "Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.",
keywords = "Metastatic, Non-clear cell, Renal cell carcinoma, Targeted agents, Treatment",
author = "Sankin, {Alexander I.} and Hakimi, {A. Ari} and Hsieh, {James J.} and Molina, {Ana M.}",
year = "2015",
doi = "10.3389/fonc.2015.00067",
language = "English (US)",
volume = "5",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Metastatic non-clear cell renal cell carcinoma

T2 - An evidence based review of current treatment strategies

AU - Sankin, Alexander I.

AU - Hakimi, A. Ari

AU - Hsieh, James J.

AU - Molina, Ana M.

PY - 2015

Y1 - 2015

N2 - Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

AB - Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

KW - Metastatic

KW - Non-clear cell

KW - Renal cell carcinoma

KW - Targeted agents

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84934293960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934293960&partnerID=8YFLogxK

U2 - 10.3389/fonc.2015.00067

DO - 10.3389/fonc.2015.00067

M3 - Article

AN - SCOPUS:84934293960

VL - 5

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - APR

M1 - 67

ER -